GlycoNex's SPD8 Phase 3 Trial Meets Primary Endpoint, Plans Taiwan Drug Approval Application Next Year
NQ Score
0/100
N1 Content Completeness
9
AI Summary (NQ-processed)
Taiwan's GlycoNex, in collaboration with Mitsubishi Gas Chemical, announced that its Denosumab biosimilar SPD8 for reducing bone loss has successfully met pre-defined equivalence criteria in a Phase 3 clinical trial. The company plans to complete the trial report in September, apply for Japanese drug approval, and then apply for Taiwan drug approval next year, targeting market launch by the end of 2027.
AI Analysis
Frequently Asked Questions
- Q: What is SPD8?
- A: It is a biosimilar of Denosumab, an osteoporosis drug, co-developed by GlycoNex and Mitsubishi Gas Chemical.
- Q: What were the Phase 3 trial results for SPD8?
- A: The trial successfully met its pre-defined equivalence criteria.
- Q: When is SPD8 expected to launch in Taiwan?
- A: The target launch date is the end of 2027.